Yerlikaya, Seda
Broger, Tobias
Isaacs, Chris
Bell, David
Holtgrewe, Lydia
Gupta-Wright, Ankur
Nahid, Payam
Cattamanchi, Adithya
Denkinger, Claudia M.
Funding for this research was provided by:
National Institutes of Health (U01AI152087)
Medizinische Fakultät Heidelberg der Universität Heidelberg
Article History
Received: 21 August 2023
Accepted: 1 November 2023
First Online: 30 November 2023
Declarations
:
: Authors declare no financial conflict of interest. P.N., A.C., and C.D. are the principal investigators of the R2D2 TB Network. S.Y., T.B., C.I, and D.B., A.G. are consultants or staff of the R2D2 TB Network. T.B. holds patents in the fields of LAM detection and aerosol collection, and is a shareholder of Avelo Ltd, a Swiss diagnostics company. C.I. is the founder and director of Connected Diagnostics Limited, a UK-based commercial entity that assists companies with the development of diagnostic devices. D.B. is the chief medical officer of Hemex Health, a diagnostics development company, and consults for other diagnostic entities.